2017至2023年美国成人中瘦型代谢功能障碍相关脂肪性肝病的当前负担
研究分析2017至2023年美国国家健康与营养调查中2965名瘦型成人(≥18岁),瘦型脂肪性肝病年龄调整患病率为12.8%,其中瘦型代谢功能障碍相关脂肪性肝病为9.3%,MetALD为1.3%,酒精相关肝病为1.0%;MASLD组中显著纤维化、进展期纤维化和肝硬化分别占5.6%、2.4%和2.0%。
要点
- 瘦型成人脂肪性肝病年龄调整患病率为12.8%。
- 瘦型MASLD患病率为9.3%,MetALD为1.3%,ALD为1.0%。
- 瘦型MASLD组中显著纤维化占5.6%,进展期纤维化占2.4%,肝硬化占2.0%。
核心结论
- 美国瘦型成人中瘦型脂肪性肝病年龄调整患病率为12.8%,瘦型MASLD为9.3%,MetALD为1.3%,ALD为1.0%。
研究设计与样本
- 研究分析2017至2023年美国国家健康与营养调查中2965名瘦型成人(≥18岁)的数据。
主要发现
- 瘦型脂肪性肝病年龄调整患病率为12.8%。
- 瘦型MASLD患病率为9.3%,MetALD为1.3%,ALD为1.0%。
- MASLD组中显著纤维化占5.6%,进展期纤维化占2.4%,肝硬化占2.0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-related and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) among lean adults in the US. Analysing data from 2965 lean adults (≥ 18 years) from the National Health and Nutrition Examination Survey (2017-2023), we found the age-adjusted prevalence of lean SLD to be 12.8%. Specifically, the prevalence was 9.3% for lean MASLD, 1.3% for MetALD and 1.0% for ALD. Notably, within the MASLD group, significant fibrosis, advanced fibrosis, and cirrhosis were observed in 5.6%, 2.4% and 2.0%, respectively.
引用
- Kim D, Danpanichkul P, Wijarnpreecha K, et al. Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017-2023. Aliment Pharmacol Ther. 2025. PMID: 39797575. doi:10.1111/apt.18501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。